Here are the 424B prospectus supplements from Park Ha Biological Technology Co., Ltd. (BYAH) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BYAH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BYAH filings page.
Park Ha Biological Technology Co., Ltd. is registering 1,133,332 Class A Ordinary Shares and pre-funded warrants exercisable for up to 200,000 Class A Ordinary Shares. The prospectus supplement states the per-share public offering price is $1.50 and each Pre-Funded Warrant is priced at $1.49999 with an exercise price of $0.00001 per share, subject to a beneficial ownership cap of 4.99% (or at the holder's prior election, 9.99%). The filing lists 4,543,884 Class A Ordinary Shares and 381,000 Class B Ordinary Shares outstanding prior to this offering and shows pro forma Class A outstanding of 5,677,216 (or 5,877,216 if Pre-Funded Warrants are exercised). The company estimates net proceeds of approximately $1.74M assuming full exercise of the Pre-Funded Warrants and states proceeds will be used for working capital and general corporate purposes.
Park Ha Biological Technology Co., Ltd. is offering 21,875,000 Units, each with one Class A Ordinary Share and one Warrant, and registering 196,875,000 Class A Ordinary Shares issuable upon Warrant exercise. The public offering price is $0.112 per Unit, for a maximum gross proceed of $2,450,000 on a best-efforts basis.
Each Warrant initially allows purchase of one Class A Ordinary Share at $0.112 for one year, but also includes a zero exercise price option under which holders may receive nine Class A Ordinary Shares per Warrant for no additional consideration, up to 196,875,000 shares in total. The company expects no meaningful cash proceeds from Warrant exercises and plans to use estimated net offering proceeds of about $2.142 million mainly to expand directly operated stores.
Class A Ordinary Shares trade on Nasdaq as “BYAH.” The company operates skincare product development and franchised stores in China through PRC subsidiaries, with revenues primarily from product sales and franchise fees, and highlights extensive regulatory, structural, and PRC-related legal and cash-transfer risks, as well as dual-class voting control concentrated with its founder.